RASA1 protein expression in HCT116 with upregulated miR-21 was significantly lower than that in those with downregulated miR-21. The ability of proliferation in HCT116, RKO with upregulated miR-21 was enhanced over time and vice versa. Conclusion: RASA1 can be a promising molecular target for therapeutic intervention in patients with colon cancer. Key Word(s): 1. miR-21; 2. RASA1; 3. colon cancer; 4. KRAS; Presenting Author: PING DU Additional Authors: NINGNING CONG,
FAJUAN SHEN, QINGYU ZHANG, CHUNSHENG KANG Corresponding Author: QINGYU BMS-777607 mw ZHANG, CHUNSHENG KANG Affiliations: Department of Gastroenterology, General Hospital of Tianjin Medical University; Laboratory of Neuro-oncology, Tian jin Neurological Institute Objective: Wnt/β-catenin signaling pathway is widely studied in many tumors including gastric cancer, which is a leading cause of death in China. Gastric adenocarcinoma is the most common type of gastric cancer. When Wnt/β-catenin signaling pathway is activated, the combination of β-catenin and T-cell factor / Lymphoid enhancer-binding factor (TCF/LEF) is necessary for the expression downstream factors
such as c-Myc and cyclin-D1. We use β-catenin/Tcf inhibitor FH535 to observe its effect on proliferation and invasion of gastric adenocarcinoma cell line SGC-7901 in vivo and in vitro. Methods: Human gastric adenocarcinoma SGC-7901 cells and human glioblastoma LN229 cells were treated with 20 μmol/L FH535 and solvent DMSO for 48 h respectively. HM781-36B purchase The cell cycle and apoptosis of treated cells were analyzed by flow cytometry. The invasive ability of SGC-7901 and LN-229 cells was determined by Transwell assay. We also used wound healing test to evaluate the cell migrating ability. Western-blot was used to find the malignancy related protein alteration. Subcutaneous tumor xenograft model was adopted to detect the influence of FH535 on SGC-7901 cell in vivo. 0.3 mg FH535 was delivered to each mice via intraperitoneal
injection every two days. FH535 was totally injected 6 times. Curve of tumor growth was plotted to describe the proliferation of SGC-7901 cell in vivo. Immunohistochemistry analysis and TUNEL Tolmetin staining were carried out to evaluate the apoptosis and proliferation state of SGC-7901 cells in vivo. Results: The experiments shows that the group treated with FH535 had significantly higher percentage of cells blocked at G0/G1 phase, lower percentage of cell cloning, less trans-membrane cell numbers, lower migrating rate after 48 h than the other groups. Protein levels of cyclin-D1 and c-Myc decreased in the FH535 group. While there was no significant difference on the percentage of apoptotic cells between the FH535 group and the others. The tumor from FH535 group grew slower than the other two groups. Immunohistochemistry analysis showed higher level of caspase-3 and lower level of Proliferating Cell Nuclear Antigen (PCNA) in the tumor tissue from FH535 group.